Share best practices through case studies on how to apply evolving technologies to meet production demands (including those related to biohazard emergencies) and learn tactics to minimize dependence on clean rooms for product integrity and worker safety.
This session will address evolving issues relative to the current state of vaccine manufacturing, how the industry is dealing with these challenges and how technologies are evolving to improve the business. There will also be an emphasis on vaccine manufacturing strategies that might be useful in aseptic production of other pharmaceuticals.
Various approaches and case studies will be presented. One key paradigm addressed will be the trend toward reduction of the physical envelope around the process, and the advantages of “closing” processes. This approach emphasizes the use of appropriate equipment, rather than relying on highly controlled facilities.
At the conclusion of this session, participants will be able to: